Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on Hard-to-Treat lymphoma in early trial

NCT ID NCT05741359

Recruiting now Disease control Sponsor: Bioray Laboratories Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 08, 2026 · Updated 20 times

Summary

This early-phase study tests a new type of CAR-T cell therapy (BRL-201) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to target cancer cells and designed to be safer by integrating into a specific gene. The main goals are to find the safest dose and check for side effects in about 12-18 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, China

    Contact

  • Tianjin Institute of Hematology

    RECRUITING

    Tianjin, Tianjin Municipality, China

    Contact

  • Wuhan Union Hospital

    RECRUITING

    Wuhan, Hubei, China

    Contact

Conditions

Explore the condition pages connected to this study.

NON-HODGKIN LYMPHOMA,B CELL